NCT00963573View on ClinicalTrials.gov

Efficacy & Safety of Loratadine-Betamethasone Oral Solution for Treatment of Severe Perennial Allergic Rhinitis in Children (Study P03428)

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

November 30, 2006

Study Completion Date

November 30, 2006

Conditions
Rhinitis
Interventions
DRUG

Loratadine

loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg

DRUG

Betamethasone

loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00963573 - Efficacy & Safety of Loratadine-Betamethasone Oral Solution for Treatment of Severe Perennial Allergic Rhinitis in Children (Study P03428) | Biotech Hunter | Biotech Hunter